Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

Dominantly Inherited Alzheimer Network (DIAN)Recruiting
NCT00869817N/AUpdated Jul 20, 2026
Sponsor: Washington University School of Medicine
Alzheimer's Disease
United States, Argentina, Australia, Brazil, Canada +8 more
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALSTerminated
NCT04569084Phase 3Updated Jul 20, 2026
Sponsor: Shionogi
ALS
United States, Canada, Germany, Italy, Japan +2 more
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruiting
NCT06500702Phase 2Updated Jul 20, 2026
Sponsor: Sanofi
Focal Segmental Glomerulosclerosis · Glomerulonephritis Minimal Lesion
United States, Argentina, Australia, Brazil, Canada +17 more
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruiting
NCT06119581Phase 3Updated Jul 20, 2026
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis
United States, Australia, Austria, Belgium, Brazil +24 more
Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy SubjectsCompleted
NCT05887791NAUpdated Jul 20, 2026
Sponsor: Rousselot BVBA
Healthy · Prediabetic State
Germany
The BD Liverty™ TIPS Stent Graft StudyActive Not Recruiting
NCT05711316NAUpdated Jul 20, 2026
Sponsor: C. R. Bard
Portal Hypertension · TIPS
United States, France, Germany
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionRecruiting
NCT07155226Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Acute Lymphoblastic Leukaemia · Acute Myeloid Leukaemia · Higher-risk Myelodysplastic Syndromes
United States, Australia, Canada, Denmark, Germany +4 more
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis DiagnosisRecruiting
NCT06978660N/AUpdated Jul 20, 2026
Sponsor: Idoven 1903 S.L.
Transthyretin Cardiac Amyloidosis
United States, France, Germany, Spain, United Kingdom
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive Not Recruiting
NCT06662383Phase 3Updated Jul 20, 2026
Sponsor: Eli Lilly and Company
Obesity
United States, Argentina, Germany, Poland, Puerto Rico
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung CancerCompleted
NCT05775289Phase 2Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer
United States, Australia, Belgium, Brazil, France +6 more
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)Enrolling By Invitation
NCT06723106Phase 1Updated Jul 17, 2026
Sponsor: Chugai Pharmaceutical
Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)
Australia, Austria, Bulgaria, Canada, Croatia +14 more
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruiting
NCT05723198Phase 3Updated Jul 17, 2026
Sponsor: Eli Lilly and Company
Areata Alopecia · Alopecia · Hypotrichosis · Hair Diseases
United States, Argentina, Australia, Canada, France +7 more
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisCompleted
NCT05990725Phase 3Updated Jul 17, 2026
Sponsor: Almirall, S.A.
Atopic Dermatitis · Eczema
Germany, Netherlands, United Kingdom
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompleted
NCT05305664Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Hyperlipoproteinemia(a)
Germany
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive Not Recruiting
NCT05425940Phase 3Updated Jul 17, 2026
Sponsor: Exelixis
Colorectal Cancer
United States, Australia, Belgium, France, Germany +11 more
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.Terminated
NCT05111626Phase 3Updated Jul 17, 2026
Sponsor: Amgen
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
United States, Argentina, Australia, Austria, Belgium +24 more
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral SclerosisRecruiting
NCT07571174Phase 1Updated Jul 17, 2026
Sponsor: Eli Lilly and Company
Amyotrophic Lateral Sclerosis
Belgium, Canada, Germany, Netherlands, Spain
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Recruiting
NCT06380738N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Germany
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightActive Not Recruiting
NCT05567796Phase 3Updated Jul 17, 2026
Sponsor: Novo Nordisk A/S
Obesity
United States, Argentina, Australia, Belgium, Bulgaria +18 more
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsActive Not Recruiting
NCT05669755Phase 3Updated Jul 17, 2026
Sponsor: Novo Nordisk A/S
Cardiovascular Disease
United States, Argentina, Australia, Brazil, Bulgaria +20 more
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive Not Recruiting
NCT03732677Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Muscle Invasive Bladder Cancer
United States, Australia, Belgium, Brazil, Canada +17 more
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9Recruiting
NCT07186842Phase 1, Phase 2Updated Jul 17, 2026
Sponsor: BioNTech SE
Advanced Solid Cancers
United States, Australia, Germany, Spain, United Kingdom
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Active Not Recruiting
NCT06456346Phase 3Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Essential Thrombocythemia
United States, Argentina, Australia, Austria, Canada +18 more
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)Recruiting
NCT07571200Phase 1Updated Jul 17, 2026
Sponsor: Eli Lilly and Company
Amyotrophic Lateral Sclerosis
Belgium, Canada, Germany, Netherlands, Spain
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active Not Recruiting
NCT04603495Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Myelofibrosis · Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
United States, Australia, Austria, Belgium, Canada +17 more

Previous page Next page